HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • 2023 Salary Survey
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • Find Out More
  • Industry Events
    • Webinars
    • Conferences
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists

ICER Faces Backlash for Proposed Changes to Value-Assessment Framework

The Institute for Clinical and Economic Review has received industry backlash over changes to its value-assessment process it proposed in June. The changes, if implemented, would lower the threshold ranges for cost-effectiveness down to $50,000 to $100,000 a year, a net drop of $50,000 at each end […]

more info 07/07/2023View Related Articles
Bookmark and Share

Samsung and Pfizer Expand Collaboration to Accelerate Biosimilar Production

Samsung Biologics and Pfizer have announced they are expanding their current collaboration to ramp up production of biosimilars, bringing the agreement to a value of $897 million. The announcement comes as Pfizer and another branch of Samsung both prepare for US launches of their Humira […]

more info 07/05/2023View Related Articles
Bookmark and Share

US Senator Bernie Sanders Looks to Cap Prices on Publicly Funded Drugs

US Senator Bernie Sanders (I – VT) is looking to include price caps on drugs developed with federal funding into a reauthorization of the 2006 Pandemic and All-Hazards Preparedness Act. The proposal would place a ceiling price that matches the lowest price for a given drug in France, Germany, Japan, […]

more info 07/05/2023View Related Articles
Bookmark and Share

ICER to Perform Value-Assessment for KarXT Schizophrenia Treatment

The Institute for Clinical and Economic Review (ICER) will perform a value-assessment on KarXT (xanomeline tartrate/trospium chloride), Karuna Therapeutics’ experimental therapeutic for schizophrenia. Public discussion of the assessment will take place next February at the 2024 New England CEPAC […]

more info 07/05/2023View Related Articles
Bookmark and Share

Amicus Therapeutics Gets EU Approval for Pompe Disease Drug

Amicus Therapeutics has received approval from the European Commission (EC) for Opfolda (miglustat), its treatment for Pompe disease, a rare disorder that causes progressive muscle weakness. The approval specifically covers the drug in combination with Pombiliti (cipaglucosidase alfa). Results from […]

more info 07/04/2023View Related Articles
Bookmark and Share

A Wave of Humira Biosimilars Hit the US Market

Several new biosimilars to AbbVie’s Humira (adalimumab) have just hit the US market in the past week, bringing a new wave of competition for the expensive top-selling therapeutic of all time. The copycats come from companies like Organon, Samsung Bioepsis, Sandoz, and Boehringer Ingelheim. Hadlima, […]

more info 07/04/2023View Related Articles
Bookmark and Share

CMS Publishes Revised Guidance for Medicare Drug Pricing Negotiations

As the upcoming Medicare drug pricing negotiations approach, the US Centers for Medicare and Medicaid Services (CMS) have released a revised guidance that better outlines the process. Pharma companies and industry groups have been anxiously awaiting such clarification, but the new information has […]

more info 07/03/2023View Related Articles
Bookmark and Share

CMS Makes Changes to Upcoming Medicare Drug Pricing Negotiations

In response to a series of lawsuits from the pharma industry, the US Centers for Medicare and Medicaid Services (CMS) have announced changes to upcoming Medicare drug pricing negotiations. The agency dialed back a confidentiality policy associated with the negotiations, a sticking point for some […]

more info 07/03/2023View Related Articles
Bookmark and Share

The Next US Presidency Doesn’t Look Friendly to Pharma

No matter who wins the next US presidency, it doesn’t look that there will be a friend to the pharma and biotech industries in the White House, according to a new Axios article. Donald Trump, the current Republican front-runner has already repeated his previous campaign promise of not letting the US […]

more info 06/30/2023View Related Articles
Bookmark and Share

ICER Founder and President to Leave Position This Year

The Institute for Clinical and Economic Review (ICER) has announced that its founder, Steve Pearson, MD, will step down from his role as president later this year. ICER’s COO Sarah Edmond will take over the position as president, while Pearson will move to an advisory position for the organization, […]

more info 06/29/2023View Related Articles
Bookmark and Share

  • 1
  • 2
  • 3
  • …
  • 110
  • Next Page

 

Advertise With Us!View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Webinar of the Week
Conference of the Week
Link of the Week

HealthEconomics.Com Jobs Portal

  • Senior Financial Analyst
  • Sr. Manager of HEOR Analytics
  • Manager of Commercial Analytics
  • Senior Director, Evidence Synthesis
  • Biostatistical Analyst
 
Syndicated Reports

Biotech R&D: a target-rich environment

Global Gene Therapy Report 2022-2031

ePrescribing Market – This is How Key Players are Dominating Global Industry

Health Economics and Outcomes Research (HEOR) Services Market to 2028

 
White Papers

Real World Evidence Solutions Global Market Report 2022

AI for Pharma and Biotech Market Pricing Strategy, Industry Latest News, Top Company Analysis, Research Report Analysis and Share by Forecast 2026

Whitepaper – Engaging the End Prescriber: A Practical Guide to Working With Physicians

Adaptive Trial Designs in Early Oncology: Minimizing Risk & Accelerating Timelines

HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Jobs
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • 2023 Salary Survey
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence & Access Marketplace
    • About the Marketplace
    • Visit the Marketplace
    • Find Out More
  • Industry Events
    • Webinars
    • Conferences
    • Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists